nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—CYP2D6—Carteolol—glaucoma	0.136	0.26	CbGbCtD
Amsacrine—CYP2D6—Betaxolol—glaucoma	0.0916	0.176	CbGbCtD
Amsacrine—CYP2D6—Methazolamide—glaucoma	0.0694	0.133	CbGbCtD
Amsacrine—ABCB1—Timolol—glaucoma	0.0626	0.12	CbGbCtD
Amsacrine—CYP2D6—Timolol—glaucoma	0.059	0.113	CbGbCtD
Amsacrine—ABCB1—Clonidine—glaucoma	0.0533	0.102	CbGbCtD
Amsacrine—CYP2D6—Clonidine—glaucoma	0.0502	0.0962	CbGbCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—POU4F2—glaucoma	0.0105	0.13	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—POU4F1—glaucoma	0.00573	0.0715	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor beta network—C3—glaucoma	0.00459	0.0572	CbGpPWpGaD
Amsacrine—TOP2A—Alprenolol—Metipranolol—glaucoma	0.00283	0.588	CbGdCrCtD
Amsacrine—NCOA3—FOXA1 transcription factor network—SOD1—glaucoma	0.00245	0.0305	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—ATOH7—glaucoma	0.00242	0.0302	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—CAV2—glaucoma	0.00217	0.027	CbGpPWpGaD
Amsacrine—ABCB1—ABC-family proteins mediated transport—PEX19—glaucoma	0.00203	0.0254	CbGpPWpGaD
Amsacrine—TOP2A—Alprenolol—Betaxolol—glaucoma	0.00198	0.412	CbGdCrCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.00185	0.023	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—SOD1—glaucoma	0.00181	0.0226	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—NCK2—glaucoma	0.00178	0.0222	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.00163	0.0203	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—C3—glaucoma	0.00144	0.0179	CbGpPWpGaD
Amsacrine—NCOA3—PPARA activates gene expression—ABCA1—glaucoma	0.00132	0.0164	CbGpPWpGaD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—glaucoma	0.00129	0.0161	CbGpPWpGaD
Amsacrine—NCOA3—FOXA1 transcription factor network—CDKN1B—glaucoma	0.00117	0.0146	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CAV1—glaucoma	0.00102	0.0127	CbGpPWpGaD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL1A—glaucoma	0.00101	0.0126	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—OPN4—glaucoma	0.000964	0.012	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IL1A—glaucoma	0.000918	0.0114	CbGpPWpGaD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—glaucoma	0.000889	0.0111	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000861	0.0107	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CA5A—glaucoma	0.000811	0.0101	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—NARFL—glaucoma	0.000811	0.0101	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NCK2—glaucoma	0.000731	0.00912	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MMP1—glaucoma	0.000696	0.00868	CbGpPWpGaD
Amsacrine—CYP2D6—Tamoxifen metabolism—CYP1B1—glaucoma	0.000675	0.00842	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000662	0.00825	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—CAV1—glaucoma	0.00063	0.00786	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BAD—glaucoma	0.000627	0.00782	CbGpPWpGaD
Amsacrine—Feeling abnormal—Apraclonidine—glaucoma	0.000579	0.00147	CcSEcCtD
Amsacrine—Stomatitis—Betaxolol—glaucoma	0.000579	0.00147	CcSEcCtD
Amsacrine—Vomiting—Methazolamide—glaucoma	0.000578	0.00147	CcSEcCtD
Amsacrine—Gastrointestinal pain—Apraclonidine—glaucoma	0.000575	0.00146	CcSEcCtD
Amsacrine—Rash—Methazolamide—glaucoma	0.000573	0.00146	CcSEcCtD
Amsacrine—Dermatitis—Methazolamide—glaucoma	0.000572	0.00146	CcSEcCtD
Amsacrine—Nausea—Carbachol—glaucoma	0.000572	0.00145	CcSEcCtD
Amsacrine—Infection—Travoprost—glaucoma	0.00057	0.00145	CcSEcCtD
Amsacrine—Headache—Methazolamide—glaucoma	0.000569	0.00145	CcSEcCtD
Amsacrine—Cardiac disorder—Clonidine—glaucoma	0.000568	0.00144	CcSEcCtD
Amsacrine—Paraesthesia—Acetazolamide—glaucoma	0.000565	0.00144	CcSEcCtD
Amsacrine—Hypotension—Brimonidine—glaucoma	0.000564	0.00143	CcSEcCtD
Amsacrine—Nausea—Levobunolol—glaucoma	0.000563	0.00143	CcSEcCtD
Amsacrine—Infection—Brinzolamide—glaucoma	0.000563	0.00143	CcSEcCtD
Amsacrine—Tachycardia—Travoprost—glaucoma	0.00056	0.00142	CcSEcCtD
Amsacrine—Skin disorder—Travoprost—glaucoma	0.000557	0.00142	CcSEcCtD
Amsacrine—Abdominal pain—Apraclonidine—glaucoma	0.000556	0.00141	CcSEcCtD
Amsacrine—Angiopathy—Clonidine—glaucoma	0.000555	0.00141	CcSEcCtD
Amsacrine—Rash—Latanoprost—glaucoma	0.000554	0.00141	CcSEcCtD
Amsacrine—Agranulocytosis—Betaxolol—glaucoma	0.000554	0.00141	CcSEcCtD
Amsacrine—Dermatitis—Latanoprost—glaucoma	0.000554	0.00141	CcSEcCtD
Amsacrine—Tachycardia—Brinzolamide—glaucoma	0.000553	0.00141	CcSEcCtD
Amsacrine—Mediastinal disorder—Clonidine—glaucoma	0.000552	0.0014	CcSEcCtD
Amsacrine—Headache—Latanoprost—glaucoma	0.000551	0.0014	CcSEcCtD
Amsacrine—Skin disorder—Brinzolamide—glaucoma	0.00055	0.0014	CcSEcCtD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—glaucoma	0.00055	0.00686	CbGpPWpGaD
Amsacrine—Anorexia—Dorzolamide—glaucoma	0.000549	0.0014	CcSEcCtD
Amsacrine—Confusional state—Pilocarpine—glaucoma	0.000549	0.0014	CcSEcCtD
Amsacrine—Arrhythmia—Clonidine—glaucoma	0.000547	0.00139	CcSEcCtD
Amsacrine—Decreased appetite—Acetazolamide—glaucoma	0.000547	0.00139	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000543	0.00138	CcSEcCtD
Amsacrine—Bradycardia—Betaxolol—glaucoma	0.000543	0.00138	CcSEcCtD
Amsacrine—Fatigue—Acetazolamide—glaucoma	0.000542	0.00138	CcSEcCtD
Amsacrine—Paraesthesia—Brimonidine—glaucoma	0.000542	0.00138	CcSEcCtD
Amsacrine—Infection—Pilocarpine—glaucoma	0.000541	0.00138	CcSEcCtD
Amsacrine—Alopecia—Clonidine—glaucoma	0.000541	0.00138	CcSEcCtD
Amsacrine—Nausea—Methazolamide—glaucoma	0.00054	0.00137	CcSEcCtD
Amsacrine—Hypotension—Dorzolamide—glaucoma	0.000539	0.00137	CcSEcCtD
Amsacrine—Dyspnoea—Brimonidine—glaucoma	0.000538	0.00137	CcSEcCtD
Amsacrine—Mental disorder—Clonidine—glaucoma	0.000536	0.00136	CcSEcCtD
Amsacrine—Hypotension—Travoprost—glaucoma	0.000536	0.00136	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000535	0.00668	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—TNF—glaucoma	0.000534	0.00666	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Pilocarpine—glaucoma	0.000533	0.00136	CcSEcCtD
Amsacrine—Tachycardia—Pilocarpine—glaucoma	0.000532	0.00135	CcSEcCtD
Amsacrine—Hypoaesthesia—Betaxolol—glaucoma	0.00053	0.00135	CcSEcCtD
Amsacrine—Hypotension—Brinzolamide—glaucoma	0.000529	0.00135	CcSEcCtD
Amsacrine—KCNH2—Neuronal System—SLC6A13—glaucoma	0.000523	0.00652	CbGpPWpGaD
Amsacrine—CYP2D6—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000521	0.0065	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Brimonidine—glaucoma	0.000521	0.00132	CcSEcCtD
Amsacrine—Fatigue—Brimonidine—glaucoma	0.00052	0.00132	CcSEcCtD
Amsacrine—Anorexia—Pilocarpine—glaucoma	0.000519	0.00132	CcSEcCtD
Amsacrine—Feeling abnormal—Acetazolamide—glaucoma	0.000518	0.00132	CcSEcCtD
Amsacrine—Hypersensitivity—Apraclonidine—glaucoma	0.000518	0.00132	CcSEcCtD
Amsacrine—Paraesthesia—Dorzolamide—glaucoma	0.000518	0.00132	CcSEcCtD
Amsacrine—Pain—Brimonidine—glaucoma	0.000516	0.00131	CcSEcCtD
Amsacrine—Dyspnoea—Dorzolamide—glaucoma	0.000514	0.00131	CcSEcCtD
Amsacrine—Dyspnoea—Travoprost—glaucoma	0.000512	0.0013	CcSEcCtD
Amsacrine—Hypotension—Pilocarpine—glaucoma	0.000509	0.00129	CcSEcCtD
Amsacrine—Paraesthesia—Brinzolamide—glaucoma	0.000509	0.00129	CcSEcCtD
Amsacrine—Dyspnoea—Brinzolamide—glaucoma	0.000505	0.00128	CcSEcCtD
Amsacrine—Asthenia—Apraclonidine—glaucoma	0.000504	0.00128	CcSEcCtD
Amsacrine—Vision blurred—Clonidine—glaucoma	0.000502	0.00128	CcSEcCtD
Amsacrine—Decreased appetite—Dorzolamide—glaucoma	0.000501	0.00127	CcSEcCtD
Amsacrine—Urticaria—Acetazolamide—glaucoma	0.0005	0.00127	CcSEcCtD
Amsacrine—Body temperature increased—Acetazolamide—glaucoma	0.000497	0.00126	CcSEcCtD
Amsacrine—Fatigue—Dorzolamide—glaucoma	0.000497	0.00126	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Travoprost—glaucoma	0.000495	0.00126	CcSEcCtD
Amsacrine—Fatigue—Travoprost—glaucoma	0.000495	0.00126	CcSEcCtD
Amsacrine—Cardiac disorder—Betaxolol—glaucoma	0.000495	0.00126	CcSEcCtD
Amsacrine—Pain—Dorzolamide—glaucoma	0.000493	0.00125	CcSEcCtD
Amsacrine—Decreased appetite—Brinzolamide—glaucoma	0.000493	0.00125	CcSEcCtD
Amsacrine—Weight decreased—Timolol—glaucoma	0.000492	0.00125	CcSEcCtD
Amsacrine—Pain—Travoprost—glaucoma	0.000491	0.00125	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000489	0.00124	CcSEcCtD
Amsacrine—Paraesthesia—Pilocarpine—glaucoma	0.000489	0.00124	CcSEcCtD
Amsacrine—Asthenia—Bimatoprost—glaucoma	0.000489	0.00124	CcSEcCtD
Amsacrine—Fatigue—Brinzolamide—glaucoma	0.000489	0.00124	CcSEcCtD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000487	0.00607	CbGpPWpGaD
Amsacrine—Dyspnoea—Pilocarpine—glaucoma	0.000486	0.00123	CcSEcCtD
Amsacrine—Pain—Brinzolamide—glaucoma	0.000485	0.00123	CcSEcCtD
Amsacrine—Angiopathy—Betaxolol—glaucoma	0.000484	0.00123	CcSEcCtD
Amsacrine—Diarrhoea—Apraclonidine—glaucoma	0.000481	0.00122	CcSEcCtD
Amsacrine—Mediastinal disorder—Betaxolol—glaucoma	0.00048	0.00122	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—NOS3—glaucoma	0.000477	0.00595	CbGpPWpGaD
Amsacrine—Arrhythmia—Betaxolol—glaucoma	0.000476	0.00121	CcSEcCtD
Amsacrine—Feeling abnormal—Dorzolamide—glaucoma	0.000475	0.00121	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000474	0.00591	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—PAX6—glaucoma	0.000473	0.00591	CbGpPWpGaD
Amsacrine—Decreased appetite—Pilocarpine—glaucoma	0.000473	0.0012	CcSEcCtD
Amsacrine—Feeling abnormal—Travoprost—glaucoma	0.000473	0.0012	CcSEcCtD
Amsacrine—Gastrointestinal pain—Dorzolamide—glaucoma	0.000471	0.0012	CcSEcCtD
Amsacrine—Alopecia—Betaxolol—glaucoma	0.000471	0.0012	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Pilocarpine—glaucoma	0.00047	0.0012	CcSEcCtD
Amsacrine—Gastrointestinal pain—Travoprost—glaucoma	0.000469	0.00119	CcSEcCtD
Amsacrine—Feeling abnormal—Brinzolamide—glaucoma	0.000467	0.00119	CcSEcCtD
Amsacrine—Mental disorder—Betaxolol—glaucoma	0.000467	0.00119	CcSEcCtD
Amsacrine—Pain—Pilocarpine—glaucoma	0.000466	0.00118	CcSEcCtD
Amsacrine—Dizziness—Apraclonidine—glaucoma	0.000465	0.00118	CcSEcCtD
Amsacrine—Malnutrition—Betaxolol—glaucoma	0.000464	0.00118	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND2—glaucoma	0.000461	0.00575	CbGpPWpGaD
Amsacrine—Urticaria—Dorzolamide—glaucoma	0.000458	0.00116	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000456	0.00569	CbGpPWpGaD
Amsacrine—Abdominal pain—Dorzolamide—glaucoma	0.000456	0.00116	CcSEcCtD
Amsacrine—Body temperature increased—Dorzolamide—glaucoma	0.000456	0.00116	CcSEcCtD
Amsacrine—Abdominal pain—Travoprost—glaucoma	0.000454	0.00115	CcSEcCtD
Amsacrine—Agranulocytosis—Timolol—glaucoma	0.000453	0.00115	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—FGFR1OP—glaucoma	0.000452	0.00564	CbGpPWpGaD
Amsacrine—Asthenia—Acetazolamide—glaucoma	0.000451	0.00115	CcSEcCtD
Amsacrine—Dizziness—Bimatoprost—glaucoma	0.000451	0.00115	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000451	0.00115	CcSEcCtD
Amsacrine—Urticaria—Brinzolamide—glaucoma	0.00045	0.00114	CcSEcCtD
Amsacrine—Feeling abnormal—Pilocarpine—glaucoma	0.000449	0.00114	CcSEcCtD
Amsacrine—Vomiting—Apraclonidine—glaucoma	0.000447	0.00114	CcSEcCtD
Amsacrine—Gastrointestinal pain—Pilocarpine—glaucoma	0.000445	0.00113	CcSEcCtD
Amsacrine—Hypersensitivity—Brimonidine—glaucoma	0.000445	0.00113	CcSEcCtD
Amsacrine—Bradycardia—Timolol—glaucoma	0.000443	0.00113	CcSEcCtD
Amsacrine—Dermatitis—Apraclonidine—glaucoma	0.000443	0.00113	CcSEcCtD
Amsacrine—Headache—Apraclonidine—glaucoma	0.00044	0.00112	CcSEcCtD
Amsacrine—Confusional state—Clonidine—glaucoma	0.000439	0.00112	CcSEcCtD
Amsacrine—Vision blurred—Betaxolol—glaucoma	0.000437	0.00111	CcSEcCtD
Amsacrine—Asthenia—Brimonidine—glaucoma	0.000433	0.0011	CcSEcCtD
Amsacrine—Infection—Clonidine—glaucoma	0.000432	0.0011	CcSEcCtD
Amsacrine—Body temperature increased—Pilocarpine—glaucoma	0.000431	0.00109	CcSEcCtD
Amsacrine—Abdominal pain—Pilocarpine—glaucoma	0.000431	0.00109	CcSEcCtD
Amsacrine—Diarrhoea—Acetazolamide—glaucoma	0.00043	0.00109	CcSEcCtD
Amsacrine—Rash—Bimatoprost—glaucoma	0.00043	0.00109	CcSEcCtD
Amsacrine—Dermatitis—Bimatoprost—glaucoma	0.000429	0.00109	CcSEcCtD
Amsacrine—Anaemia—Betaxolol—glaucoma	0.000429	0.00109	CcSEcCtD
Amsacrine—Connective tissue disorder—Timolol—glaucoma	0.000428	0.00109	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—glaucoma	0.000427	0.00533	CbGpPWpGaD
Amsacrine—Headache—Bimatoprost—glaucoma	0.000427	0.00109	CcSEcCtD
Amsacrine—Thrombocytopenia—Clonidine—glaucoma	0.000426	0.00108	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RAB8A—glaucoma	0.000425	0.0053	CbGpPWpGaD
Amsacrine—Hypersensitivity—Dorzolamide—glaucoma	0.000425	0.00108	CcSEcCtD
Amsacrine—Tachycardia—Clonidine—glaucoma	0.000424	0.00108	CcSEcCtD
Amsacrine—Hypersensitivity—Travoprost—glaucoma	0.000423	0.00108	CcSEcCtD
Amsacrine—Skin disorder—Clonidine—glaucoma	0.000422	0.00107	CcSEcCtD
Amsacrine—CYP2D6—Melatonin metabolism and effects—EDN1—glaucoma	0.000421	0.00526	CbGpPWpGaD
Amsacrine—Nausea—Apraclonidine—glaucoma	0.000418	0.00106	CcSEcCtD
Amsacrine—Hypersensitivity—Brinzolamide—glaucoma	0.000417	0.00106	CcSEcCtD
Amsacrine—Dizziness—Acetazolamide—glaucoma	0.000416	0.00106	CcSEcCtD
Amsacrine—Anorexia—Clonidine—glaucoma	0.000415	0.00105	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN2B—glaucoma	0.000414	0.00516	CbGpPWpGaD
Amsacrine—Asthenia—Dorzolamide—glaucoma	0.000414	0.00105	CcSEcCtD
Amsacrine—Asthenia—Travoprost—glaucoma	0.000412	0.00105	CcSEcCtD
Amsacrine—Asthenia—Brinzolamide—glaucoma	0.000407	0.00103	CcSEcCtD
Amsacrine—Hypotension—Clonidine—glaucoma	0.000406	0.00103	CcSEcCtD
Amsacrine—Nausea—Bimatoprost—glaucoma	0.000405	0.00103	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—FGFR1OP—glaucoma	0.000404	0.00504	CbGpPWpGaD
Amsacrine—Cardiac disorder—Timolol—glaucoma	0.000404	0.00103	CcSEcCtD
Amsacrine—Hypersensitivity—Pilocarpine—glaucoma	0.000401	0.00102	CcSEcCtD
Amsacrine—Vomiting—Acetazolamide—glaucoma	0.0004	0.00102	CcSEcCtD
Amsacrine—Dizziness—Brimonidine—glaucoma	0.000399	0.00101	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CA1—glaucoma	0.000396	0.00494	CbGpPWpGaD
Amsacrine—Angiopathy—Timolol—glaucoma	0.000395	0.001	CcSEcCtD
Amsacrine—Diarrhoea—Dorzolamide—glaucoma	0.000394	0.001	CcSEcCtD
Amsacrine—Headache—Acetazolamide—glaucoma	0.000394	0.001	CcSEcCtD
Amsacrine—Diarrhoea—Travoprost—glaucoma	0.000393	0.000998	CcSEcCtD
Amsacrine—Mediastinal disorder—Timolol—glaucoma	0.000392	0.000998	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000392	0.000997	CcSEcCtD
Amsacrine—Asthenia—Pilocarpine—glaucoma	0.000391	0.000994	CcSEcCtD
Amsacrine—Paraesthesia—Clonidine—glaucoma	0.000391	0.000993	CcSEcCtD
Amsacrine—Arrhythmia—Timolol—glaucoma	0.000389	0.000989	CcSEcCtD
Amsacrine—Dyspnoea—Clonidine—glaucoma	0.000388	0.000986	CcSEcCtD
Amsacrine—Diarrhoea—Brinzolamide—glaucoma	0.000388	0.000986	CcSEcCtD
Amsacrine—Alopecia—Timolol—glaucoma	0.000385	0.000978	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CTSA—glaucoma	0.000384	0.00479	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—SLC6A1—glaucoma	0.000383	0.00477	CbGpPWpGaD
Amsacrine—Confusional state—Betaxolol—glaucoma	0.000382	0.000971	CcSEcCtD
Amsacrine—Mental disorder—Timolol—glaucoma	0.000381	0.00097	CcSEcCtD
Amsacrine—Dizziness—Dorzolamide—glaucoma	0.000381	0.000969	CcSEcCtD
Amsacrine—Rash—Brimonidine—glaucoma	0.000381	0.000968	CcSEcCtD
Amsacrine—Dermatitis—Brimonidine—glaucoma	0.00038	0.000967	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—RAB8A—glaucoma	0.00038	0.00474	CbGpPWpGaD
Amsacrine—Dizziness—Travoprost—glaucoma	0.000379	0.000965	CcSEcCtD
Amsacrine—Malnutrition—Timolol—glaucoma	0.000379	0.000964	CcSEcCtD
Amsacrine—Headache—Brimonidine—glaucoma	0.000378	0.000961	CcSEcCtD
Amsacrine—Decreased appetite—Clonidine—glaucoma	0.000378	0.000961	CcSEcCtD
Amsacrine—Infection—Betaxolol—glaucoma	0.000376	0.000957	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Clonidine—glaucoma	0.000375	0.000955	CcSEcCtD
Amsacrine—Fatigue—Clonidine—glaucoma	0.000375	0.000953	CcSEcCtD
Amsacrine—Dizziness—Brinzolamide—glaucoma	0.000375	0.000953	CcSEcCtD
Amsacrine—Nausea—Acetazolamide—glaucoma	0.000373	0.00095	CcSEcCtD
Amsacrine—Diarrhoea—Pilocarpine—glaucoma	0.000373	0.000948	CcSEcCtD
Amsacrine—Pain—Clonidine—glaucoma	0.000372	0.000946	CcSEcCtD
Amsacrine—Thrombocytopenia—Betaxolol—glaucoma	0.000371	0.000943	CcSEcCtD
Amsacrine—Tachycardia—Betaxolol—glaucoma	0.00037	0.00094	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—OPTN—glaucoma	0.000369	0.0046	CbGpPWpGaD
Amsacrine—Skin disorder—Betaxolol—glaucoma	0.000368	0.000935	CcSEcCtD
Amsacrine—Vomiting—Dorzolamide—glaucoma	0.000366	0.000932	CcSEcCtD
Amsacrine—Rash—Dorzolamide—glaucoma	0.000363	0.000924	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—VEGFA—glaucoma	0.000363	0.00453	CbGpPWpGaD
Amsacrine—Dermatitis—Dorzolamide—glaucoma	0.000363	0.000923	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CA2—glaucoma	0.000362	0.00452	CbGpPWpGaD
Amsacrine—Rash—Travoprost—glaucoma	0.000362	0.00092	CcSEcCtD
Amsacrine—Dermatitis—Travoprost—glaucoma	0.000361	0.000919	CcSEcCtD
Amsacrine—Headache—Dorzolamide—glaucoma	0.000361	0.000918	CcSEcCtD
Amsacrine—Anorexia—Betaxolol—glaucoma	0.000361	0.000918	CcSEcCtD
Amsacrine—Vomiting—Brinzolamide—glaucoma	0.00036	0.000916	CcSEcCtD
Amsacrine—Dizziness—Pilocarpine—glaucoma	0.00036	0.000916	CcSEcCtD
Amsacrine—Headache—Travoprost—glaucoma	0.00036	0.000914	CcSEcCtD
Amsacrine—Nausea—Brimonidine—glaucoma	0.000358	0.000912	CcSEcCtD
Amsacrine—Feeling abnormal—Clonidine—glaucoma	0.000358	0.000911	CcSEcCtD
Amsacrine—Rash—Brinzolamide—glaucoma	0.000357	0.000909	CcSEcCtD
Amsacrine—Vision blurred—Timolol—glaucoma	0.000357	0.000908	CcSEcCtD
Amsacrine—Dermatitis—Brinzolamide—glaucoma	0.000357	0.000908	CcSEcCtD
Amsacrine—Gastrointestinal pain—Clonidine—glaucoma	0.000356	0.000904	CcSEcCtD
Amsacrine—Headache—Brinzolamide—glaucoma	0.000355	0.000903	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000354	0.00442	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000354	0.00442	CbGpPWpGaD
Amsacrine—Hypotension—Betaxolol—glaucoma	0.000354	0.0009	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000354	0.00441	CbGpPWpGaD
Amsacrine—Vomiting—Pilocarpine—glaucoma	0.000346	0.000881	CcSEcCtD
Amsacrine—Urticaria—Clonidine—glaucoma	0.000345	0.000879	CcSEcCtD
Amsacrine—Abdominal pain—Clonidine—glaucoma	0.000344	0.000874	CcSEcCtD
Amsacrine—Body temperature increased—Clonidine—glaucoma	0.000344	0.000874	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—NGFR—glaucoma	0.000344	0.00429	CbGpPWpGaD
Amsacrine—Rash—Pilocarpine—glaucoma	0.000343	0.000873	CcSEcCtD
Amsacrine—Dermatitis—Pilocarpine—glaucoma	0.000343	0.000872	CcSEcCtD
Amsacrine—CYP2D6—Melatonin metabolism and effects—APOE—glaucoma	0.000343	0.00428	CbGpPWpGaD
Amsacrine—Nausea—Dorzolamide—glaucoma	0.000342	0.000871	CcSEcCtD
Amsacrine—Headache—Pilocarpine—glaucoma	0.000341	0.000868	CcSEcCtD
Amsacrine—Nausea—Travoprost—glaucoma	0.000341	0.000867	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.00034	0.00424	CbGpPWpGaD
Amsacrine—Paraesthesia—Betaxolol—glaucoma	0.00034	0.000865	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000339	0.00423	CbGpPWpGaD
Amsacrine—Dyspnoea—Betaxolol—glaucoma	0.000338	0.000858	CcSEcCtD
Amsacrine—Nausea—Brinzolamide—glaucoma	0.000337	0.000856	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—OPTN—glaucoma	0.00033	0.00411	CbGpPWpGaD
Amsacrine—Decreased appetite—Betaxolol—glaucoma	0.000329	0.000837	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Betaxolol—glaucoma	0.000327	0.000831	CcSEcCtD
Amsacrine—Fatigue—Betaxolol—glaucoma	0.000326	0.00083	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—NTRK1—glaucoma	0.000326	0.00407	CbGpPWpGaD
Amsacrine—Pain—Betaxolol—glaucoma	0.000324	0.000823	CcSEcCtD
Amsacrine—Nausea—Pilocarpine—glaucoma	0.000323	0.000823	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.00032	0.000815	CcSEcCtD
Amsacrine—Hypersensitivity—Clonidine—glaucoma	0.00032	0.000815	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—NGF—glaucoma	0.000314	0.00391	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000313	0.00391	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000312	0.0039	CbGpPWpGaD
Amsacrine—Asthenia—Clonidine—glaucoma	0.000312	0.000793	CcSEcCtD
Amsacrine—Feeling abnormal—Betaxolol—glaucoma	0.000312	0.000793	CcSEcCtD
Amsacrine—Confusional state—Timolol—glaucoma	0.000312	0.000793	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000311	0.00388	CbGpPWpGaD
Amsacrine—Infection—Timolol—glaucoma	0.000307	0.000781	CcSEcCtD
Amsacrine—Urticaria—Betaxolol—glaucoma	0.000301	0.000765	CcSEcCtD
Amsacrine—Skin disorder—Timolol—glaucoma	0.0003	0.000764	CcSEcCtD
Amsacrine—Body temperature increased—Betaxolol—glaucoma	0.000299	0.000761	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—glaucoma	0.000298	0.00371	CbGpPWpGaD
Amsacrine—Diarrhoea—Clonidine—glaucoma	0.000298	0.000757	CcSEcCtD
Amsacrine—Anorexia—Timolol—glaucoma	0.000295	0.00075	CcSEcCtD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000291	0.00363	CbGpPWpGaD
Amsacrine—Hypotension—Timolol—glaucoma	0.000289	0.000735	CcSEcCtD
Amsacrine—Dizziness—Clonidine—glaucoma	0.000288	0.000731	CcSEcCtD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000287	0.00359	CbGpPWpGaD
Amsacrine—Hypersensitivity—Betaxolol—glaucoma	0.000279	0.000709	CcSEcCtD
Amsacrine—Paraesthesia—Timolol—glaucoma	0.000278	0.000706	CcSEcCtD
Amsacrine—Vomiting—Clonidine—glaucoma	0.000277	0.000703	CcSEcCtD
Amsacrine—Dyspnoea—Timolol—glaucoma	0.000276	0.000701	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—glaucoma	0.000274	0.00342	CbGpPWpGaD
Amsacrine—Rash—Clonidine—glaucoma	0.000274	0.000697	CcSEcCtD
Amsacrine—Dermatitis—Clonidine—glaucoma	0.000274	0.000697	CcSEcCtD
Amsacrine—Headache—Clonidine—glaucoma	0.000272	0.000693	CcSEcCtD
Amsacrine—Asthenia—Betaxolol—glaucoma	0.000272	0.000691	CcSEcCtD
Amsacrine—Decreased appetite—Timolol—glaucoma	0.000269	0.000684	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Timolol—glaucoma	0.000267	0.000679	CcSEcCtD
Amsacrine—Fatigue—Timolol—glaucoma	0.000267	0.000678	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000266	0.00332	CbGpPWpGaD
Amsacrine—Pain—Timolol—glaucoma	0.000265	0.000673	CcSEcCtD
Amsacrine—Diarrhoea—Betaxolol—glaucoma	0.000259	0.000659	CcSEcCtD
Amsacrine—Nausea—Clonidine—glaucoma	0.000258	0.000657	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—FAS—glaucoma	0.000256	0.00319	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—TXN—glaucoma	0.000255	0.00318	CbGpPWpGaD
Amsacrine—Feeling abnormal—Timolol—glaucoma	0.000255	0.000648	CcSEcCtD
Amsacrine—Gastrointestinal pain—Timolol—glaucoma	0.000253	0.000643	CcSEcCtD
Amsacrine—Dizziness—Betaxolol—glaucoma	0.00025	0.000637	CcSEcCtD
Amsacrine—Urticaria—Timolol—glaucoma	0.000246	0.000625	CcSEcCtD
Amsacrine—Body temperature increased—Timolol—glaucoma	0.000245	0.000622	CcSEcCtD
Amsacrine—Abdominal pain—Timolol—glaucoma	0.000245	0.000622	CcSEcCtD
Amsacrine—Vomiting—Betaxolol—glaucoma	0.000241	0.000612	CcSEcCtD
Amsacrine—Rash—Betaxolol—glaucoma	0.000239	0.000607	CcSEcCtD
Amsacrine—Dermatitis—Betaxolol—glaucoma	0.000239	0.000607	CcSEcCtD
Amsacrine—Headache—Betaxolol—glaucoma	0.000237	0.000603	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN2A—glaucoma	0.000237	0.00295	CbGpPWpGaD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000236	0.00295	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000233	0.00291	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000232	0.00289	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.000231	0.00288	CbGpPWpGaD
Amsacrine—Hypersensitivity—Timolol—glaucoma	0.000228	0.00058	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000228	0.00284	CbGpPWpGaD
Amsacrine—Nausea—Betaxolol—glaucoma	0.000225	0.000572	CcSEcCtD
Amsacrine—Asthenia—Timolol—glaucoma	0.000222	0.000564	CcSEcCtD
Amsacrine—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000213	0.00265	CbGpPWpGaD
Amsacrine—Diarrhoea—Timolol—glaucoma	0.000212	0.000538	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN1B—glaucoma	0.000209	0.00261	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MMP2—glaucoma	0.000209	0.0026	CbGpPWpGaD
Amsacrine—Dizziness—Timolol—glaucoma	0.000205	0.00052	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—IL1A—glaucoma	0.000199	0.00249	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—GSTT1—glaucoma	0.000198	0.00247	CbGpPWpGaD
Amsacrine—Vomiting—Timolol—glaucoma	0.000197	0.0005	CcSEcCtD
Amsacrine—Rash—Timolol—glaucoma	0.000195	0.000496	CcSEcCtD
Amsacrine—Dermatitis—Timolol—glaucoma	0.000195	0.000495	CcSEcCtD
Amsacrine—Headache—Timolol—glaucoma	0.000194	0.000493	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—glaucoma	0.000187	0.00233	CbGpPWpGaD
Amsacrine—Nausea—Timolol—glaucoma	0.000184	0.000467	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—FAS—glaucoma	0.000178	0.00222	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—C3—glaucoma	0.000175	0.00219	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND2—glaucoma	0.000169	0.00211	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.000168	0.00209	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	0.00016	0.00199	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000159	0.00198	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—ABCA1—glaucoma	0.000158	0.00197	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP1B1—glaucoma	0.000158	0.00197	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTT1—glaucoma	0.000157	0.00196	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MMP9—glaucoma	0.000157	0.00196	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	0.000155	0.00194	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN2B—glaucoma	0.000152	0.00189	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND2—glaucoma	0.000151	0.00189	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.00015	0.00187	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—glaucoma	0.00015	0.00187	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000144	0.00179	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—VEGFA—glaucoma	0.000141	0.00176	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN2B—glaucoma	0.000136	0.00169	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.000132	0.00165	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—TNF—glaucoma	0.000128	0.0016	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—GSTM1—glaucoma	0.000126	0.00157	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—CYP1B1—glaucoma	0.000125	0.00156	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	0.000124	0.00154	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—TNF—glaucoma	0.000121	0.0015	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CA5A—glaucoma	0.000117	0.00146	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NARFL—glaucoma	0.000117	0.00146	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.000113	0.00141	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000112	0.0014	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—MTHFR—glaucoma	0.000111	0.00139	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NARFL—glaucoma	0.00011	0.00138	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CA5A—glaucoma	0.00011	0.00138	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—APOE—glaucoma	0.000104	0.00129	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000103	0.00129	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CAV1—glaucoma	0.000103	0.00128	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000103	0.00128	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	0.000102	0.00127	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTM1—glaucoma	0.0001	0.00125	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	9.97e-05	0.00124	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	9.89e-05	0.00123	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	9.58e-05	0.0012	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—glaucoma	9.57e-05	0.00119	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—VEGFA—glaucoma	8.81e-05	0.0011	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	8.77e-05	0.00109	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN2A—glaucoma	8.67e-05	0.00108	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—NOS3—glaucoma	7.77e-05	0.000969	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN2A—glaucoma	7.76e-05	0.000967	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN1B—glaucoma	7.68e-05	0.000958	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—TNF—glaucoma	7.55e-05	0.000941	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	7.5e-05	0.000936	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTGS2—glaucoma	7.11e-05	0.000887	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	7.01e-05	0.000875	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN1B—glaucoma	6.87e-05	0.000857	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CA1—glaucoma	5.72e-05	0.000713	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CTSA—glaucoma	5.54e-05	0.000691	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	5.52e-05	0.000688	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CA1—glaucoma	5.39e-05	0.000672	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CA2—glaucoma	5.23e-05	0.000652	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	5.23e-05	0.000652	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CTSA—glaucoma	5.22e-05	0.000651	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CA2—glaucoma	4.93e-05	0.000615	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	4.35e-05	0.000542	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—glaucoma	4.32e-05	0.000538	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	3.72e-05	0.000465	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TXN—glaucoma	3.68e-05	0.00046	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TXN—glaucoma	3.47e-05	0.000433	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	3.28e-05	0.00041	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTT1—glaucoma	2.86e-05	0.000356	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTT1—glaucoma	2.69e-05	0.000336	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—ABCA1—glaucoma	2.28e-05	0.000284	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP1B1—glaucoma	2.28e-05	0.000284	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP1B1—glaucoma	2.15e-05	0.000268	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ABCA1—glaucoma	2.15e-05	0.000268	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTM1—glaucoma	1.82e-05	0.000227	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTM1—glaucoma	1.71e-05	0.000214	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—MTHFR—glaucoma	1.61e-05	0.000201	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—MTHFR—glaucoma	1.52e-05	0.000189	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—APOE—glaucoma	1.5e-05	0.000187	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CAV1—glaucoma	1.48e-05	0.000185	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—APOE—glaucoma	1.41e-05	0.000176	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CAV1—glaucoma	1.4e-05	0.000174	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NOS3—glaucoma	1.12e-05	0.00014	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NOS3—glaucoma	1.06e-05	0.000132	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTGS2—glaucoma	1.03e-05	0.000128	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTGS2—glaucoma	9.67e-06	0.000121	CbGpPWpGaD
